154913-23-2

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(4-bromophenyl)piperidin-4-one is utilized as a key compound in the research and development of novel pharmaceuticals, specifically targeting the treatment of various psychiatric and neurological disorders. Its application is driven by its ability to modulate dopamine receptor activity, which is crucial in managing conditions such as schizophrenia, bipolar disorder, and Parkinson's disease.
Used in Medicinal Chemistry and Drug Discovery:
In the field of medicinal chemistry, 1-(4-bromophenyl)piperidin-4-one serves as a valuable compound due to its pharmacological properties and structural features. It is employed in the design and synthesis of new drug candidates, potentially leading to the discovery of more effective treatments for a range of disorders. Its role in drug discovery is underscored by its potential to contribute to the development of innovative therapeutic strategies.

Upstream product

• 3592-25-4 1,5-dichloropentan-3-one 
• 106-40-1 4-bromo-aniline 
• 106-37-6 1.4-dibromobenzene 
• 589-87-7 1,4-bromoiodobenzene 

Downstream Products

• 1226154-84-2 1-(4-bromophenyl)piperidin-4-ol 
• 1430472-09-5 1-(4-bromophenyl)-4-methylpiperidin-4-ol 
• 1430472-06-2 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-one 

Relevant academic research and scientific papers

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

NEW AZABENZIMIDAZOLE DERIVATIVES

The present invention relates to compounds of general formula I, wherein the group R1, R2, X, Y and z are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

AZABENZIMIDAZOLE DERIVATIVES

The present invention relates to compounds of general formula (I), wherein the group R1, R2, X, Y and z are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Synthesis and exploratory photophysical investigation of donor-bridge-acceptor systems derived from N-substituted 4-piperidones

We report a two-step synthesis for N-aryl- and N-alkyl-substituted 4-piperidones, in which the N substituent can easily be varied.A number of intramolecular donor-acceptor systems was synthesized from these piperidones by conversion of the carbonyl functionality.The influence of the N-aryl donor on the electronic absorption and fluorescence spectra was investigated systematically.It was concluded that some systems can be used as efficient fluorescent probes with a high sensitivity for solvent polarity.